FY26 pharmacy takeda DEC
Ended Awarded Last action
- Contract number
- 15B50926F00000027
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Federal Correctional Institution Fort Worth
Correctional Facilities, Department of Justice
- Obligated
- $148,019
Award facts
- Contract value 100% obligated
- $148,019.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lexington, MA 02421, USA
Award details come from SAM.gov/FPDS.
About this award
The Federal Correctional Institution Fort Worth awarded a $148,019.16 firm fixed-price delivery order to Takeda Pharmaceuticals America Inc. on October 1, 2025, with an ultimate completion date of January 30, 2026. This delivery order, issued under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB), represents a child contract to Takeda's broader single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center valued at $131.0 million for the period July 15, 2025, through July 14, 2026. The delivery order carries no set-aside designation, reflecting the specialized and often single-source nature of the pharmaceutical products involved. Performance will occur at Takeda's headquarters location in Lexington, Massachusetts.
Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, specializes in developing and distributing advanced pharmaceutical products across therapeutic areas including rare diseases, hematology, immunology, and oncology. Under the GSA schedule vehicle and associated BPA, Takeda supplies critical medications to federal correctional institutions and other federal healthcare entities, including products such as CINRYZE and KALBITOR for hereditary angioedema, ADVATE and OBIZUR for hemophilia, and GAMMAGARD and other immune globulin products for immunological conditions. The company maintains an active portfolio of federal contracts supporting healthcare operations across the Department of Veterans Affairs, Department of Justice Bureau of Prisons, and other federal agencies, demonstrating a consistent track record as a prime federal contractor for specialized biopharmaceutical procurement.
Quick answers
Who was awarded contract 15B50926F00000027?
15B50926F00000027 was awarded to Takeda Pharmaceuticals America, Inc. by Federal Correctional Institution Fort Worth (Correctional Facilities) on October 1, 2025.
How much is contract 15B50926F00000027 worth?
The government has obligated $148,019 on 15B50926F00000027.
Is contract 15B50926F00000027 an order under another contract?
Yes. 15B50926F00000027 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 15B50926F00000027 competed?
The extent of competition for 15B50926F00000027 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award